Atlas Trials

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

Clinical trial NCT05019040 · COMPLETED

Trial details

NCT number
NCT05019040
Sponsor
Zhejiang Palo Alto Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Chronic HBV Infection
Start date
2021-09-17
Primary completion
2022-11-15
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.